Hereditary progressive dystonia with marked diurnal fluctuation

Area of Science:

• Neurogenetics
• Movement Disorders
• Biochemistry

Background:

• Hereditary progressive dystonia with marked diurnal fluctuation (HPD/DRD) is an autosomal dominant disorder.
• It is caused by mutations in the GTP cyclohydrolase I (GCH 1) gene, leading to reduced tetrahydrobiopterin (BH4) and tyrosine hydroxylase (TH) synthesis.
• This selectively impacts nigrostriatal dopamine (DA) neuron terminals, particularly in the ventral striatum.

Purpose of the Study:

• To elucidate the pathophysiology of HPD/DRD.
• To understand the molecular basis of the disorder and its clinical manifestations.
• To investigate the therapeutic efficacy of levodopa.

Main Methods:

• Genetic analysis of the GCH 1 gene.
• Biochemical assays to measure TH and DA activity.
• Clinical observation of age-dependent symptoms and diurnal fluctuations.
• Assessment of levodopa treatment response.

Main Results:

• GCH 1 gene abnormalities lead to decreased BH4 and TH, affecting DA synthesis in the nigrostriatal pathway.
• This results in postural dystonia and tremor, but spares parkinsonian features.
• Levodopa effectively alleviates motor symptoms and improves growth, with sustained efficacy and no side effects.
• Age-dependent clinical course reflects variations in TH activity and pathway maturation.

Conclusions:

• HPD/DRD pathophysiology involves selective dopaminergic dysfunction due to GCH 1 mutations.
• Levodopa is a highly effective and safe treatment for HPD/DRD, addressing both motor and growth impairments.
• Understanding the genetic and biochemical basis explains the unique clinical presentation and therapeutic response.